Time to read
Deborah Gold, Chief Executive of National AIDS Trust, said:
“Long-acting injectables have been proven to be a safe and effective method of delivering HIV treatment, so we are delighted that NICE has approved the use of cabotegravir with rilpivirine for adults living with HIV.
“The voice of people living with HIV is clear: they want this technology available as part of a range of treatment options. It won’t be right for everyone but, for some, monthly injections are highly preferable to daily pills.
“Innovations that can make it easier for people to stick to their treatment plans both improve the wellbeing of people living with HIV and bring us one step closer to the goal of ending transmissions by 2030.”